You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Whilst therapeutic advances using anti-platelet and anti-coagulation drugs have been made to address cardiovascular diseases, they have significant drawbacks, including bleeding complications. Our aim was to develop a targeted anti-thrombotic therapy to deliver a therapeutic payload directly to the site of the thrombi, thereby preventing bleeding side effects.Methods:We have genetically designed and engineered an activated platelet targeted recombinant fusion protein with the tick anticoagulant peptide (Targ-TAP). A non-binding single-chain antibody fused with an active TAP (Mut-TAP) was used as control.ResultsFlow cytometry assays (both human and mouse) demonstrated the binding affinity of Targ-TAP specifically to activated platelets (ADP, CRP and TRAP), while no binding was observed with Mut-TAP (p